1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Market Access Impact: HIV (EU5)

Market Access Impact: HIV (EU5)

  • April 2016
  • ID: 3866827
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents




Can prescription barriers help the 2nd and 3rd place HIV brands catch up to the runaway market leader?


In the European HIV treatment market, the leading brand is comfortably ahead—but can market barriers help either of the 3rd-place contenders move up to the #2 spot.

Market Access Impact: HIV shows you which brands you’re losing share to, which brands you’re taking it from, and why.

Market Access Impact: HIV explores how cost concerns and other barriers affect market share for 8 major HIV treatments: Celsentri, Evotaz, Intelence, Isentress, Stribild, Triumeq, Truvada, and Viread.

You’ll find out which brands your brand is losing share to, which ones you’re taking it from, and why—information you can use to compete more effectively.

Not your market? Click here to see the US report






Get Answers to Key Questions about HIV Drug Brands


Celsentri (maraviroc; ViiV Healthcare): Which two leading FDCs does Celsentri take the most share from?
Evotaz (atazanavir/cobicistat; BMS): Which barrier do more than twice as many doctors experience with Evotaz than any other brand?
Intelence (etravirine; Janssen Therapeutics): Is limited availability or patient preference a bigger issue for doctors prescribing Intelence?
Isentress (raltegravir; Merck & Co.): Isentress and Stribild are prescribed equally. Which brand has better awareness among doctors?
Stribild (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Gilead): Which market barrier costs Stribild more than twice as much share as any other?
Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare): Nearly half of Triumeq’s share loss is to one other brand. Which one?
Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead): Which barrier is responsible for over a third of Truvada’s net share gain?
Viread (tenofovir disoproxil fumarate; Gilead): Viread sees a net share gain from all but two surveyed brands. Which two?


Top Takeaways

Clear winners and losers: The two most prescribed brands have the biggest market share and barrier-related gains, while the two least prescribed brands have the smallest share and the greatest losses.
Half of brands benefit from barriers: But the two biggest winners see significantly bigger gains than the other two brands.
Brand awareness is high: With one exception, at least 97% of doctors surveyed are aware of any given brand.
Barrier effect is uneven: The number of doctors who experience the top 2 market barriers varies greatly from brand to brand.
No clear advantage for FDCs vs. monotherapies: Of the four most prescribed brands, two are fixed-dose products while the other two are monotherapies.
Cost and labelling issues have the greatest impact: Barriers related to guidelines and patient type restrictions affect more prescriptions than any others.
Barrier effect significant for “other” brands: Taken together, “other” brands have a greater market share than 3/4 of the surveyed brands, and see the third biggest net gain due to barriers.

Exploring Market Access Issues
Market Access Impact: HIV explores key issues affecting HIV drug manufacturers. You’ll learn:

How barriers affect market access:

What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest effect?

How barriers affect your brand:

How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?


A Report Based on Expert Knowledge

We surveyed 150 infectious disease specialists — 30 from each EU5 country (France, Italy, Germany, Spain, UK) — chosen from the largest community of validated physicians in the world.

All respondents have:

Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with melanoma in total in the last month

We conducted the survey between March 2nd and 9th, 2016.







Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Antiviral Drug Resistance Market to 2027 - Global Analysis and Forecasts By Product, Disease Indication, Technology, End User, and Geography

Antiviral Drug Resistance Market to 2027 - Global Analysis and Forecasts By Product, Disease Indication, Technology, End User, and Geography

  • $ 4550
  • August 2019

The global antiviral drug resistance market is expected to reach US$ 4,573.24 Mn in 2027 from US$ 2,572.26 Mn in 2018. The Antiviral drug resistance market is estimated to grow with a CAGR of 6.8% from ...

Global Antivirals Drug Industry

Global Antivirals Drug Industry

  • $ 5450
  • October 2019

Antivirals Drug market worldwide is projected to grow by US$13.7 Billion, driven by a compounded growth of 3.9%. Nucleotide Polymerase Inhibitors, one of the segments analyzed and sized in this study, ...

Global Cancer Diagnostics Partnering 2014-2019: Deal trends, players and financials

Global Cancer Diagnostics Partnering 2014-2019: Deal trends, players and financials

  • $ 2995
  • November 2019

The Global Cancer Diagnostics Partnering 2014-2019 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare c ...


ref:plp2016

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on